Zachary Klaassen hosts Andrew Hahn to discuss future directions in metastatic castration-resistant prostate cancer. Dr. Hahn highlights the "golden era" for targeting cell surface proteins through ...

psa nadir 0.2, metastatic hormone sensitive prostate cancer, mHSPC treatment, PSA targets prostate cancer, PSA Thresholds in mHSPC: What VA Data Reveals About Optimal Targets with Stephen Freedland, ...

HIF-2 inhibitor kidney cancer, Casdatifan cabozantinib combination, refractory renal cell carcinoma treatment, AB-521 clinical trial, clear cell RCC therapy, Combination HIF-2α/VEGF Dual Inhibition in ...

CHAI biomarker, using AI to predict BCG vs Gem/Doce response in bladder cancer, achieving 90% success rate, insights on precision medicine, Computational Histology AI Guides Treatment Selection for ...

Evan Yu is joined by Atish Choudhury to discuss a first-in-human trial combining EZH2 and PARP inhibition in metastatic castration-resistant prostate cancer. Dr. Choudhury explains that EZH2 is an ...

Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical ...

Leslie Ballas speaks with Timothy Showalter about a multimodal artificial intelligence-based prostate cancer test. Dr. Showalter explains how ArteraAI analyzes H&E-stained biopsy slides using computer ...

Sam Chang interviews Alice Yu about three practice-changing areas in urothelial carcinoma. Dr. Yu first discusses the NIAGARA trial, which demonstrated improved pathologic complete response, ...

(UroToday.com) Minh Nguyen, MS2, from the Brody School of Medicine at East Carolina University, presented findings on the evolving trends in pelvic lymph node dissection (PLND) during radical ...

Urothelial carcinoma (UC) is frequently associated with a poor prognosis in patients with advanced disease. A strong biological rationale supports the investigation of combining antibody-drug ...

Muscle-invasive bladder cancer (MIBC) presents significant treatment challenges, with antibody-drug conjugates (ADCs) targeting HER2, NECTIN4, and TROP-2 emerging as promising therapeutic options.

This narrative review analyzed current practices and protocols for local anesthesia in Rezūm™ and evaluated the feasibility, pain management, and patient comfort associated with this approach.